{"id":44266,"date":"2022-05-24T13:01:30","date_gmt":"2022-05-24T11:01:30","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/"},"modified":"2022-05-24T13:01:30","modified_gmt":"2022-05-24T11:01:30","slug":"cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/","title":{"rendered":"Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva\u00ae (Docosanol Cream 10%) Including the First Approval in the Pump Format"},"content":{"rendered":"
\n

BRIDGEWATER, N.J. & VADODARA, India–(BUSINESS WIRE)–#abreva<\/a>–Cosette Pharmaceuticals, Inc (“Cosette”), in collaboration with Aleor Dermaceuticals, a wholly owned subsidiary of Alembic Pharmaceuticals (\u201cAlembic\u201d; BSE: 533573), announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for an NBE version of Abreva\u00ae (Docosanol cream 10%) in a 2 gm tube and pump formats. Shipments of the product will begin imminently.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nApurva Saraf, CEO of Cosette Pharma and Pranav Amin, MD of Alembic Pharma stated, “This approval and launch highlights our ability to successfully partner and bring important complex products to market. We look forward to launching this Private Label, Over-the-Counter product with our retail partners in the US.\u201d\n<\/p>\n

\nThis approval represents the first ANDA approval in the pump format and Cosette plans to launch the product across the US retail channel.\n<\/p>\n

\n* Abreva\u00ae is a licensed trademark of GlaxoSmithKline<\/i>\n<\/p>\n

\nAbout Cosette Pharmaceuticals, Inc.:<\/b>\n<\/p>\n

\nCosette Pharmaceuticals, Inc. is a US-based, fully integrated pharmaceutical company with capabilities in product development, manufacturing, and commercial operations. The current products focus on complex dosage forms including topical creams, ointments, oral liquids\/solutions, suppositories, and injectables. Cosette has a long history of quality manufacturing, consistent supply, and commercialization success, including two sites (New Jersey and North Carolina) supported by more than 350+ dedicated employees across all functional areas. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm. www.cosettepharma.com<\/a>\n<\/p>\n

\nFollow us on LinkedIn.<\/a>\n<\/p>\n

\nAbout Alembic Pharmaceuticals, Inc.:<\/b>\n<\/p>\n

\nAlembic Pharmaceuticals, Inc. <\/b>is a vertically integrated research and development pharmaceutical company, and has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a marketing team of over 5,000 are well recognized by doctors and patients. Information about Alembic can be found at http:\/\/www.alembicpharmaceuticals.com\/<\/a>; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLL TD) (BSE: 533573)\n<\/p>\n

Contacts<\/b> <\/p>\n

\nSerge Ilin-Schneider:<\/b> bd@cosettepharma.com<\/a>
Kian Kazemi:<\/b> sales@cosettepharma.com<\/a>
Lynn Munroe:<\/b> EGCPR@egcgroup.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BRIDGEWATER, N.J. & VADODARA, India–(BUSINESS WIRE)–#abreva–Cosette Pharmaceuticals, Inc (“Cosette”), in collaboration with Aleor Dermaceuticals, a wholly owned subsidiary of Alembic Pharmaceuticals (\u201cAlembic\u201d; BSE: 533573), announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for an NBE version of Abreva\u00ae (Docosanol cream 10%) in a 2 gm tube … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44266","6":"format-standard","7":"category-industry"},"yoast_head":"\nCosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva\u00ae (Docosanol Cream 10%) Including the First Approval in the Pump Format - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva\u00ae (Docosanol Cream 10%) Including the First Approval in the Pump Format - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BRIDGEWATER, N.J. & VADODARA, India–(BUSINESS WIRE)–#abreva–Cosette Pharmaceuticals, Inc (“Cosette”), in collaboration with Aleor Dermaceuticals, a wholly owned subsidiary of Alembic Pharmaceuticals (\u201cAlembic\u201d; BSE: 533573), announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for an NBE version of Abreva\u00ae (Docosanol cream 10%) in a 2 gm tube ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-24T11:01:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220524005173\/en\/1464253\/21\/Abreva_brand_image.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva\u00ae (Docosanol Cream 10%) Including the First Approval in the Pump Format\",\"datePublished\":\"2022-05-24T11:01:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\\\/\"},\"wordCount\":397,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524005173\\\/en\\\/1464253\\\/21\\\/Abreva_brand_image.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\\\/\",\"name\":\"Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva\u00ae (Docosanol Cream 10%) Including the First Approval in the Pump Format - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524005173\\\/en\\\/1464253\\\/21\\\/Abreva_brand_image.jpg\",\"datePublished\":\"2022-05-24T11:01:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524005173\\\/en\\\/1464253\\\/21\\\/Abreva_brand_image.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524005173\\\/en\\\/1464253\\\/21\\\/Abreva_brand_image.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva\u00ae (Docosanol Cream 10%) Including the First Approval in the Pump Format\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva\u00ae (Docosanol Cream 10%) Including the First Approval in the Pump Format - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/","og_locale":"en_US","og_type":"article","og_title":"Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva\u00ae (Docosanol Cream 10%) Including the First Approval in the Pump Format - Pharma Trend","og_description":"BRIDGEWATER, N.J. & VADODARA, India–(BUSINESS WIRE)–#abreva–Cosette Pharmaceuticals, Inc (“Cosette”), in collaboration with Aleor Dermaceuticals, a wholly owned subsidiary of Alembic Pharmaceuticals (\u201cAlembic\u201d; BSE: 533573), announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for an NBE version of Abreva\u00ae (Docosanol cream 10%) in a 2 gm tube ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-24T11:01:30+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220524005173\/en\/1464253\/21\/Abreva_brand_image.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva\u00ae (Docosanol Cream 10%) Including the First Approval in the Pump Format","datePublished":"2022-05-24T11:01:30+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/"},"wordCount":397,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220524005173\/en\/1464253\/21\/Abreva_brand_image.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/","url":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/","name":"Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva\u00ae (Docosanol Cream 10%) Including the First Approval in the Pump Format - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220524005173\/en\/1464253\/21\/Abreva_brand_image.jpg","datePublished":"2022-05-24T11:01:30+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220524005173\/en\/1464253\/21\/Abreva_brand_image.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220524005173\/en\/1464253\/21\/Abreva_brand_image.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cosette-pharmaceuticals-and-alembic-pharmaceuticals-limited-announce-the-approval-and-launch-of-a-national-brand-equivalent-nbe-of-abreva-docosanol-cream-10-including-the-first-approval-in-t\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva\u00ae (Docosanol Cream 10%) Including the First Approval in the Pump Format"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44266"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44266\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}